420 related articles for article (PubMed ID: 10897046)
21. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
[TBL] [Abstract][Full Text] [Related]
22. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
23. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
Ayyoub M; Stevanovic S; Sahin U; Guillaume P; Servis C; Rimoldi D; Valmori D; Romero P; Cerottini JC; Rammensee HG; Pfreundschuh M; Speiser D; Lévy F
J Immunol; 2002 Feb; 168(4):1717-22. PubMed ID: 11823502
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
[TBL] [Abstract][Full Text] [Related]
26. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
[TBL] [Abstract][Full Text] [Related]
27. Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s).
Imro MA; Manici S; Russo V; Consogno G; Bellone M; Rugarli C; Traversari C; Protti MP
Cancer Res; 1999 May; 59(10):2287-91. PubMed ID: 10344730
[TBL] [Abstract][Full Text] [Related]
28. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.
Bakker AB; Marland G; de Boer AJ; Huijbens RJ; Danen EH; Adema GJ; Figdor CG
Cancer Res; 1995 Nov; 55(22):5330-4. PubMed ID: 7585596
[TBL] [Abstract][Full Text] [Related]
29. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
[TBL] [Abstract][Full Text] [Related]
30. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
31. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
32. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
[TBL] [Abstract][Full Text] [Related]
33. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro.
Tjandrawan T; Martin DM; Maeurer MJ; Castelli C; Lotze MT; Storkus WJ
J Immunother; 1998 Mar; 21(2):149-57. PubMed ID: 9551367
[TBL] [Abstract][Full Text] [Related]
34. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
[TBL] [Abstract][Full Text] [Related]
36. An antigen-targeted approach to adoptive transfer therapy of cancer.
Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
[TBL] [Abstract][Full Text] [Related]
37. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope.
Zajac P; Oertli D; Spagnoli GC; Noppen C; Schaefer C; Heberer M; Marti WR
Int J Cancer; 1997 May; 71(3):491-6. PubMed ID: 9139889
[TBL] [Abstract][Full Text] [Related]
38. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
39. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
40. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
